Achieve Life Sciences, Inc. (ACHV) SEC Filings & Earnings Calls

CFO transition risk; new CFO from pharmaceutical industry may have limited biotech experience

“Mr. Halladay served in several different roles at Esperion Therapeutics, Inc., a pharmaceutical company, including as Chief Financial Officer from November 2022 until September 2026”

Dilution risk from ATM offering; no obligation to sell but potential for significant share issuance.

“may offer and sell shares of its common stock having an aggregate offering price of up to $150.0 million”

FDA CRL related to cGMP observations at prior manufacturing facility; resubmission and approval timeline risk.

“The CRL relates to outstanding current Good Manufacturing Practice (cGMP) observations from an inspection of the Company’s prior third-party manufacturing facility” · word for word

Dependence on successful NDA resubmission and FDA approval for cytisinicline; no approved products or revenue yet.

“Anticipates potential FDA approval in the first half of 2027, followed by U.S. commercial launch” · word for word

FDA CRL delays approval

“In June 2026, we received a Complete Response Letter, or CRL, from the FDA regarding our New Drug Application, or NDA, for cytisinicline relating to outstanding manufacturing-related observations from a current Good Manufacturing Practice, or cGMP, inspection of a third-party manufacturing facility and to final product labeling that was not completed by the ” · word for word

Liquidity risk from debt and no revenue

“We currently do not generate any cash flow from operations and if we are unable to make interest and/or principal payments when due, we would be in default under the New Debt Agreement.” · word for word

Single product dependency

“Cytisinicline is currently our sole product candidate and there is no guarantee that we will be able to successfully obtain approval from the U.S. Food and Drug Administration, or FDA, or other regulatory agencies to commercialize cytisinicline.” · word for word

FDA approval delay risk

“We expect to receive a Complete Response Letter, or CRL, from the FDA on or before our June 20, 2026 PDUFA targeted action date, which would delay our NDA approval.”

Manufacturing facility OAI and warning letter

“the third-party manufacturer's facility... received an Official Action Indicated, or OAI, classification and a warning letter.”

Sopharma dispute risk

“Sopharma has alleged that our engagement of third-party manufacturers is a breach of our agreement, which we have disputed and have proposed steps to resolve.”

Dilution risk from authorized share increase

“the future issuance of our common stock authorized by the amendment may, among other things, decrease existing stockholders’ percentage equity ownership and... could be dilutive to the voting rights of existing stockholders” · word for word

FDA regulatory risk from prior manufacturer's OAI classification; potential Complete Response Letter delaying cytisinicline approval.

“Achieve’s prior third-party manufacturer facility received an Official Action Indicated classification by the FDA... expects to receive a Complete Response Letter from the FDA on or before June” · word for word

Key executive departures (CCO) may disrupt commercial launch preparations.

“Jaime Xinos, the Company’s Chief Commercial Officer, will depart the Company, effective as of May 31, 2026” · word for word

FDA approval delay risk

“We expect to receive a Complete Response Letter, or CRL, from the FDA on or before our June 20, 2026 PDUFA targeted action date, which would delay our NDA approval.” · word for word

Manufacturing facility OAI and warning letter

“the third-party manufacturer's facility... received an Official Action Indicated, or OAI, classification and a warning letter.”

Sopharma dispute risk

“Sopharma has alleged that our engagement of third-party manufacturers is a breach of our agreement, which we have disputed and have proposed steps to resolve.” · word for word

Pre-revenue stage risk

“We have no products approved for commercial sale and have not generated any revenue from product sales to date.” · word for word

CEO transition risk

“Mr. Stewart resigned from his position as Chief Executive Officer on April 17, 2026.” · word for word

Pre-revenue clinical-stage company with no product revenue

“we are a clinical development-stage specialty pharmaceutical company and have not generated revenue to date.” · word for word

Dependence on FDA approval of cytisinicline

“PSUs granted that vested as to 100% on the acceptance of our New Drug Application, or NDA, for cytisinicline with the U.S. Food and Drug Administration”

FDA approval dependency

“The Common Warrants are exercisable at any time after the date of issuance, subject to certain ownership limitations, and will expire on the later of the twentieth business day following (i) the date on which the Issuer publicly announces that the U.S. Food and Drug Administration has approved cytisinicline for smoking cessation in adults (the "FDA Approval"” · word for word

FDA approval dependency

“The Common Warrants are exercisable at any time after the date of issuance, subject to certain ownership limitations, and will expire on the later of the twentieth business day following (i) the date on which the Issuer publicly announces that the U.S. Food and Drug Administration has approved cytisinicline for smoking cessation in adults (the "FDA Approval"” · word for word

Significant dilution from issuance of ~49.4M shares and up to 49.5M warrants, potentially over 100% dilution relative to current shares.

“49,418,069 shares ... Common Warrants to purchase up to 49,518,569 shares”

CEO departure creates leadership uncertainty during critical clinical and commercialization phase.

“Richard Stewart stepping down as CEO effective April 18, 2026”

Clinical trial risk: proceeds used for Phase 3 trial for e-cigarette cessation; FDA approval uncertain.

“fund a Phase 3 clinical trial for cytisinicline for e-cigarette cessation” · word for word

Going concern risk

“Substantial doubt exists as to our ability to continue as a going concern.” · word for word

Dilution risk from warrants and convertible debt

“The sale of additional shares of our common stock, the conversion of the New Convertible Term Loan into shares of our common stock, the exercise of any of our outstanding warrants, the exercise of any of our outstanding options, or the settlement of our restricted stock units would have a dilutive impact on our existing stockholders and could cause the marke” · word for word

FDA approval delay risk

“While unclear, there is potential for a delay in FDA approval beyond the PDUFA targeted action date of June 20, 2026.” · word for word

Sopharma dispute risk

“Sopharma has alleged that our engagement of third-party manufacturers is a breach of our agreement, which we have disputed and have proposed steps to resolve.” · word for word

Regulatory approval risk remains; FDA inspection observations at one manufacturer need resolution.

“One manufacturer named in the cytisinicline NDA recently underwent an FDA current Good Manufacturing Practices inspection, where two observations related to solid oral dose manufacturing were identified.” · word for word

Regulatory approval risk; PDUFA date set but approval not guaranteed.

“PDUFA date June 20, 2026; NDA under review.”

No product revenue; pre-commercial stage company with ongoing losses.

“No revenue mentioned; net loss expected.”

Going concern uncertainty

“Substantial doubt exists as to our ability to continue as a going concern.” · word for word

Sopharma manufacturing dispute

“Sopharma has alleged that our engagement of third-party manufacturers is a breach of our agreement, which we have disputed and have proposed steps to resolve.” · word for word

No approved products or revenue

“We have no products approved for commercial sale and have not generated any revenue from product sales to date.” · word for word

Dilution risk from warrants and options

“a total of 37,297,356 shares, consisting of warrants to purchase 34,098,815 shares, options exercisable for 2,114,211 shares and 1,084,330 restricted stock units, have not been included in the loss per share computation” · word for word